| Identification | Back Directory | [Name]
ACTB-1003 | [CAS]
939805-30-8 | [Synonyms]
ACTB-1003
ACTB1003;ACTB 1003
FGFR,Fibroblast growth factor receptor,Vascular endothelial growth factor receptor,inhibit,EOC317,Inhibitor,VEGFR,EOC-317,EOC 317
1-[4-[4-amino-6-(methoxymethyl)-7-(morpholin-4-ylmethyl)pyrrolo[2,1-f][1,2,4]triazin-5-yl]-2-fluorophenyl]-3-[2-fluoro-5-(trifluoromethyl)phenyl]urea
N-[4-[4-Amino-6-(methoxymethyl)-7-(4-morpholinylmethyl)pyrrolo[2,1-f][1,2,4]triazin-5-yl]-2-fluorophenyl]-N'-[2-fluoro-5-(trifluoromethyl)phenyl]urea
Urea, N-[4-[4-amino-6-(methoxymethyl)-7-(4-morpholinylmethyl)pyrrolo[2,1-f][1,2,4]triazin-5-yl]-2-fluorophenyl]-N'-[2-fluoro-5-(trifluoromethyl)phenyl] | [Molecular Formula]
C27H26F5N7O3 | [MDL Number]
MFCD25976782 | [MOL File]
939805-30-8.mol | [Molecular Weight]
591.53 |
| Chemical Properties | Back Directory | [density ]
1.51±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMF: 30 mg/ml; DMSO: 30 mg/ml; DMSO:PBS (pH 7.2) (1:2): 0.33 mg/ml; Ethanol: 1 mg/ml | [form ]
Powder | [pka]
12.47±0.70(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
ACTB-1003 is an oral kinase inhibitor which is used in the targeting of cancers. | [in vivo]
EOC317 (ACTB-1003) is shown to inhibit tumor angiogenesis evident by the inhibition of CD31 staining in tumor sections. EOC317 is combinable with 5-FU or paclitaxel without diminishing the activity or increasing the toxicity of these chemotherapy agents in the HCT-116 colon tumor xenograft model[1]. | [IC 50]
FGFR1: 6 nM (IC50); VEGFR2: 2 nM (IC50); Tie-2: 4 nM (IC50) |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
|